Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs winning bids, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs that provide significant clinical value [2]. - The procurement process was led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces, with a high selection rate of 93% among participating companies [2]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The original drugs selected include various formulations such as Fosinopril and Acarbose, with companies like Bristol-Myers Squibb and Sanofi involved [3]. - Several original drugs that had previously won bids in earlier rounds, such as Gefitinib and Clopidogrel, did not participate in this round, allowing generic competitors to dominate [4][3]. - The absence of original drugs in the procurement reflects a trend where original drugs face significant competition from generics post-patent expiration, leading to a decline in sales and profits [6]. Group 3: Market Dynamics - The "patent cliff" phenomenon has led to original drugs experiencing substantial sales and profit declines once their patents expire, which was previously mitigated by high prices and market share [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital settings [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9]. Group 4: Future Outlook - The Chinese government is implementing policies to support the development of innovative drugs, which is expected to expand the overall pharmaceutical market [10].

Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs selected, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs [2]. - The procurement process involved 51,000 medical institutions, with a high selection rate of 93% and an average of 14 companies selected per product [2][3]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The selected original drugs include various formulations from companies like Bristol-Myers Squibb, Sanofi, and Bayer, with some previously shortlisted in earlier rounds [3]. - Notable original drugs that did not participate in this round include AstraZeneca's gefitinib and Sanofi's clopidogrel, which had previously been selected [4][3]. Group 3: Market Dynamics - The phenomenon known as "patent cliff" has led to significant declines in sales and profits for original drugs post-patent expiration, making it challenging for them to maintain market share without substantial price reductions [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital procurement [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9].

2026.02. 12 本文字数：2499，阅读时长大约4分钟 作者 | 第一财经 林志吟 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获 得拟中选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、 呼吸系统、消化系统等26个治疗领域。 从这接续采购的316种药品来看，据第一财经记者统计，有原研药中标的品种共有21个，整体占比 不到一成。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的 水分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新 药，满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份 全部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资 格的企业绝大多数参与投标报价，整体中选率高达93%，每个品种平均14家企业中选。 本次接续采购，国内药品上市许可持有人（含药品注册批件持有人）、境外药品上市许可持有人及其 境内责任 ...

凭借品牌优势在院外市场找到新的发展空间。 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获得拟中 选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系 统、消化系统等26个治疗领域。 2018年以来，随着国家组织的药品集采启动，医药行业逐渐走向分水岭，过了专利保护期的原研药难以 在中国市场维持高利润且垄断局面，而原来以销售这类药物为生的跨国药企这几年已在密集调整业务， 重塑在华发展战略。 一些原研药虽然缺席集采，但并不意味着从市场消失，相反凭借品牌优势仍在院外市场找到新的发展空 间。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的水 分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新药， 满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份全 部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资格的 企业绝大多数参与投标报价 ...

Group 1 - The article discusses President Trump's health issue related to his frequent use of aspirin, which he claims has led to bruising on his hand due to high dosage and frequent handshakes [1][2] - Trump reportedly takes 325 mg of aspirin daily, significantly higher than the recommended low dose of 81 mg, which is typically advised for heart disease prevention [1][2] - Aspirin is widely used for preventing thrombus formation and is a standard treatment for various atherosclerotic diseases, including coronary heart disease and cerebrovascular diseases [1][2] Group 2 - The article highlights the importance of proper administration of aspirin to minimize gastrointestinal irritation, suggesting the use of enteric-coated aspirin and specific timing for consumption [2] - It emphasizes that daily aspirin therapy is not suitable for everyone and should be based on individual health status, age, and risk factors for heart disease or stroke [2][5] - Recent studies have raised concerns about the bleeding risks associated with long-term aspirin use, particularly in older adults, necessitating careful assessment of risks and benefits [3][5]

Core Insights - The market performance of Clopidogrel exceeded expectations, becoming a "blockbuster" drug that significantly supported Sanofi's growth and provided a capital foundation for subsequent acquisitions [1] Group 1: Company Growth and Strategy - Sanofi's merger with Genzyme initiated resource integration and product line optimization to consolidate its industry position, avoiding risks associated with patent cliffs [2] - Following the merger, Sanofi's sales surged, surpassing €30 billion in 2010, making it the fourth-largest pharmaceutical company globally [2] - Sanofi invested $17 billion in acquisitions from 2008 to 2010, enhancing its over-the-counter and generic drug lines, thereby reducing reliance on single blockbuster drugs [2] Group 2: Diversification and Innovation - After 2010, Sanofi expanded into the orphan drug sector, acquiring Genzyme for $21 billion, which helped elevate its revenue and establish it as a leader in orphan drugs [3] - Sanofi's total sales grew from €30.4 billion in 2010 to €34 billion in 2015, demonstrating resilience against the patent cliff of Clopidogrel [3] - The company underwent strategic adjustments post-2016, forming five key business segments and optimizing operations through asset swaps and acquisitions [4] Group 3: Long-term Growth and Future Prospects - Sanofi successfully navigated patent cliff crises, maintaining low debt levels while introducing new potential products like U300 insulin and Dupixent [4] - The company is actively exploring emerging fields such as RNAi and tumor immunotherapy to ensure long-term growth [4] - Sanofi's development history illustrates the importance of innovation and adaptability in a competitive market environment [5][6]

Core Viewpoint - Aspirin is widely used for the prevention of cardiovascular diseases, especially among the elderly, but its long-term use and potential side effects require careful consideration and medical guidance [1][2][3]. Group 1: Aspirin's Applications - Aspirin was initially used as an analgesic and anti-inflammatory drug but is now recognized for its ability to inhibit platelet aggregation, making it effective in preventing thrombosis [1]. - It is a standard treatment for various atherosclerotic diseases, including coronary heart disease, cerebrovascular disease, and peripheral vascular disease [1]. - Additionally, aspirin is used to prevent preeclampsia during pregnancy and to treat antiphospholipid syndrome [1]. Group 2: Proper Usage and Dosage - To minimize gastric irritation, enteric-coated aspirin has been developed, which dissolves in the intestine rather than the stomach [2]. - The recommended method for taking enteric-coated aspirin is on an empty stomach, followed by eating after 30 minutes, while regular aspirin should be taken after meals [2]. - Daily aspirin intake may reduce the risk of heart attacks and strokes, but it is not suitable for everyone and should be taken under medical advice [2]. Group 3: Risks and Considerations - There is increasing concern about the bleeding risks associated with aspirin, particularly in the elderly, necessitating careful assessment of its indications and contraindications [3]. - Long-term aspirin use can be beneficial for elderly patients with atherosclerotic diseases or high cardiovascular risk, provided that risks are properly evaluated [3]. - For most adults, occasional aspirin use for pain relief is generally safe, but daily use without a history of heart disease may not provide significant benefits and could lead to serious side effects [3].

Core Viewpoint - The company has developed DT678 tablets, a globally innovative drug for anti-platelet aggregation, which is currently in Phase II clinical trials and shows superior efficacy compared to Clopidogrel with fewer side effects [1][3]. Group 1 - DT678 tablets are a co-development between the company and DT Company, which is partially owned by the University of Michigan, with the company holding a 30% stake in DT Company [1][3]. - The company possesses exclusive rights for the development and use of the patented compound in China [1][3]. - Preliminary results from Phase I trials indicate that DT678 has over 20 times the efficacy of Clopidogrel, with advantages such as rapid onset, fewer side effects, and greater stability [3].

Summary of Conference Call Notes Industry Overview - The conference call discusses the upcoming **11th National Drug Centralized Procurement (国采)**, expected to start in **July or August 2025**. The 10th round had extreme results due to a long time span and rule adjustments, leading to potential product registration backlog issues in the 11th round, with intensified competition and possible rule changes to avoid excessive low pricing [1][4][2]. Key Points and Arguments - **11th Batch Procurement Timing**: The 11th batch is likely to be delayed until the second half of the year due to the need for medical institutions to prepare reporting volumes, with only one round expected this year [2]. - **Biological Drug Procurement**: The biological drug procurement led by Anhui is set for execution by the end of **2025**, based on insulin procurement rules, focusing on moderate price reductions and a larger number of selected products [1][5][6]. - **Quality Control Measures**: The National Medical Products Administration (药监局) is responsible for quality control of selected products, while the National Healthcare Security Administration (医保局) has introduced new rules requiring companies to have market volume before gaining market share, ensuring fair competition [7][3]. - **Impact of New Rules on Original Drug Companies**: The new procurement rules favor original drug companies by allowing them to retain some market share even if not selected, and providing hospitals with more autonomy in choosing products [12][3]. - **Price Discrimination Issues**: The centralized procurement has provided a price benchmark, but there have been instances of price discrimination across provinces, leading to a downward spiral in drug prices and potential shortages [18][19]. - **Market Dynamics for Generic Drugs**: The procurement process has increased the penetration of competitive products in grassroots hospitals, while high-priced drugs have significant market expansion potential [11][21]. Additional Important Content - **Alliance Procurement Framework**: The shift to an alliance procurement framework has led to varied approaches among provinces, with some like Hebei being aggressive in pricing, while others like Guangdong and Xinjiang adopt a more balanced approach [8][9]. - **Future Alliance Plans**: Major alliances for procurement include those led by Sichuan, Xinjiang, Guangdong, and Tianjin, with Shanghai and Jiangsu considering joining new projects [9]. - **Impact on Marketing Strategies**: Original drug companies are adjusting their marketing strategies, increasing collaboration with e-commerce channels to enhance drug accessibility and sales [22][24]. - **Medicare Payment Standards**: The establishment of Medicare payment standards is expected to significantly impact drug prices and market dynamics, potentially leading to a unified pricing structure across different regions [13][20]. - **Challenges for Innovative Drugs**: The procurement policies may limit the development of innovative drugs due to low pricing, which could discourage research and development efforts in the pharmaceutical industry [25][26]. This summary encapsulates the critical insights and implications from the conference call regarding the upcoming drug procurement policies and their potential impact on the pharmaceutical industry.

Core Viewpoint - Heng Rui Medicine has signed a $1.97 billion licensing agreement with Merck for its Lp(a) oral small molecule project, HRS-5346, granting Merck exclusive rights for development, production, and commercialization outside Greater China [1][2]. Company Summary - The agreement includes an upfront payment of $200 million from Merck, with potential milestone payments not exceeding $1.77 billion, plus sales royalties based on net sales of HRS-5346 after market launch, totaling at least $1.97 billion for Heng Rui Medicine [1][2]. - HRS-5346 is currently undergoing Phase II clinical trials in China and has the potential to reduce Lp(a) levels in the blood by over 80%, addressing a global patient population of 1.4 billion suffering from cardiovascular diseases linked to elevated Lp(a) [1][2]. - Heng Rui Medicine has been actively pursuing overseas licensing as part of its international expansion strategy, with 13 innovative drugs already licensed abroad [2]. Industry Summary - In 2024, the total upfront payments for overseas licensing in China's biopharmaceutical industry are projected to reach $4.94 billion, surpassing the $3.77 billion in financing for innovative drug research and development in the first year [3]. - Upfront payments provide direct funding for research and development, reducing reliance on equity financing for pharmaceutical companies [3].